vorinostat has been researched along with Dysembryoma in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blattmann, C | 1 |
| Oertel, S | 1 |
| Thiemann, M | 1 |
| Weber, KJ | 1 |
| Schmezer, P | 1 |
| Zelezny, O | 1 |
| Lopez Perez, R | 1 |
| Kulozik, AE | 1 |
| Debus, J | 1 |
| Ehemann, V | 1 |
1 other study available for vorinostat and Dysembryoma
| Article | Year |
|---|---|
Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Histone D | 2012 |